

LACHMAN CONSULTANT SERVICES, INC.
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE
WESTBURY, NY 11590
(516) 222-6222 • FAX (516) 688-1887

8025-01 FEB 26 A9:00

February 23, 2001

(OVERNIGHT COURIER: 2/23/01)

Dockets Management Branch
Food and Drug Administration (HFA-305)
Room 1061
5630 Fishers Lane
Rockville, Maryland 20852


**SUBJECT: Withdrawal of Citizen Petition
Docket Number 00P-1580/CP 1**

Dear Sir or Madam:

Reference is made to our October 23, 2000, Citizen Petition, Docket Number 00P-1580/CP 1, which requested that the Commissioner of the Food and Drug Administration make a determination as whether Fosamax® (Alendronate Sodium) Tablets, 35 mg and 70 mg, manufactured by Merck & Co., Inc., have been voluntarily withdrawn or withheld from sale for safety or efficacy reasons.

In light of the recent marketing of Fosamax® Tablets, 35 mg and 70 mg, by Merck & Co., we are herewith withdrawing our October 23, 2000, Citizen Petition, Docket Number 00P-1580/CP 1.

Sincerely,



Robert W. Pollock
Vice President

RP/ms

cc: L. Lachman

44P1054

00P-1580

WDL1